ql1203
mAbexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Oct 28, 2019 (NCT04234594)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06949761 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2025 | Qilu Pharmaceutical Co., Ltd. |
| NCT04233151 | Phase 3 | Jan 20, 2020 | Chinese Academy of Medical Sciences, Fudan University, Qilu Pharmaceutical Co., Ltd. |
| NCT04234594 | Phase 1 | Oct 28, 2019 | Guizhou Medical University, Qilu Pharmaceutical Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Qilu Pharmaceutical Co., Ltd. | For profit | 3 | 3 | 3 | 2019 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Guizhou Medical University | Academic/Hospital | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1